- Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
- Bavarian Nordic modtager accept fra de europæiske lægemiddelmyndigheder af registreringsansøgningen for chikungunyavaccine
- Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
- Bavarian Nordic konverterer eksisterende kreditfacilitet til bæredygtighedsrelateret lån
- Bavarian Nordic tilslutter sig globalt initiativ i kampen mod mpox i Afrika
- Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
- Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
- Bavarian Nordic indsender registreringsansøgning for chikungunyavaccine til de europæiske sundhedsmyndigheder
- Bavarian Nordic indsender registreringsansøgning for chikungunya-vaccine til de amerikanske sundhedsmyndigheder
- Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 189.50 |
---|---|
High | 189.50 |
Low | 183.85 |
Bid | 185.10 |
Offer | 185.10 |
Previous close | 190.70 |
Average volume | 254.71k |
---|---|
Shares outstanding | 78.12m |
Free float | 78.05m |
P/E (TTM) | 14.83 |
Market cap | 14.90bn DKK |
EPS (TTM) | 12.86 DKK |
Data delayed at least 15 minutes, as of Jul 25 2024 16:10 BST.
More ▼